ADVANCED SOLID TUMORS

This early-stage study tested a new drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to check safety and find the right dose. The study was stopped early, so results a…

This early-stage study tested a new drug called VVD-130850 that blocks a protein (STAT3) often active in cancers. It was given alone or with an immunotherapy to people with advanced solid tumors or blood cancers that had spread or couldn't be removed. The main goals were to check…

This study tested an experimental drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited…

This early-phase study tested a new drug called BPT567 in 20 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, so final results are not av…

This study tested an experimental oral drug (Debio 0123) combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had worsened after prior platinum-based treatment. The goal was to find the safest dose and check for side effects and early signs of t…

This study tested a new drug called BLU-222 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, so results are limited.

This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had come back or spread. The treatment uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back to fight the cancer. The study was st…

This early-phase study tested a new drug called FAZ053, which helps the immune system fight cancer, given alone or with another drug (PDR001) in 154 adults with advanced solid tumors (including triple-negative breast cancer and rare sarcomas). The main goal was to check safety an…

This early-phase study tested an experimental drug called INCB081776, alone or with another drug, in 83 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated early,…

This early-stage study tested a new drug, PF-07265028, alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head & neck cancers. The goal was to find the safest dose and see if the drugs shrink tumors. The study was terminated early…

This early-phase study tested a new drug called BAT8007 in 93 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. The study was terminated early, and no cure or long-term contr…

This early-stage study tested a new drug called BGB-30813, alone or with another drug (tislelizumab), in people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. The trial was terminated early, so resul…

This early-stage study tested a new drug, ASP2074, in 23 adults with advanced solid tumors that had spread or couldn't be removed. The main goals were to check for side effects and find a safe dose. Participants received the drug as an infusion and were monitored closely. The stu…

This early-phase study tested an experimental oral drug called ATX-559 in 17 people with advanced solid tumors (like breast, colon, or endometrial cancer) that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The stu…

This early-phase trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was ended early, so res…